Exemed to buy UCB facility in Vapi, India

Deal includes multi-year supply agreement between the two companies

India-based Exemed Pharmaceuticals, a manufacturer of active pharmaceutical ingredients, is to buy UCB’s production facility in Vapi, Gujarat, India, for an undisclosed sum.

The transaction, which is in line with UCB’s strategy to focus on bringing new drugs to patients and less on mass manufacturing, includes a multi-year supply agreement between UCB and Exemed. Approximately 80 members of staff will transfer from UCB Vapi to Exemed.

The Vapi plant currently focuses on the production, packaging and distribution of some of UCB mature drugs mainly for the Indian market; it produces around 2% of total UCB volumes.

Exemed Pharmaceuticals will continue with these activities and also plans to bring new business to the site.

Companies